Loading data for ADCT — first visit, this takes a few seconds.
ADC Therapeutics SA (ADCT)
NYSE: ADCT
· Real-Time Price · USD
1.16
+0.02 (1.75%)
At close: Aug 31, 2026, 2:22 PM
The price, the headline numbers and the latest news, in one place.
ADC Therapeutics SA (ADCT) Stock Price, Analysis & Data
1.75% (1D)
No data available
| Bid | 1.16 |
| Market Cap | 148.64M |
| Revenue (ttm) | 79.58M |
| Net Income (ttm) | -96.91M |
| 1.83 | |
| -0.58 | |
| n/a | |
| -0.78 | |
| P/B (ttm) | -0.65 |
| P/S (ttm) | 1.87 |
| Earnings Date | Nov 10, 2026 |
| Ask | 1.17 |
| Volume | 237,332 |
| Avg. Volume (20D) | 2,014,476 |
| Open | 1.13 |
| Previous Close | 1.14 |
| Day's Range | 1.12 - 1.19 |
| 52-Week Range | 0.78 - 4.98 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell l...
Sector Healthcare
IPO Date May 18, 2020
Employees 188
Stock Exchange NYSE
Ticker Symbol ADCT
Website https://www.adctherapeutics.com
Financial Performance
In 2025, ADC Therapeutics SA's revenue was 81.36M, an increase of 14.85% compared to the previous year's 70.84M. Earnings were -142.62M, a decrease of -9.64%.
Financial StatementsEarnings Surprise
ADC Therapeutics SA has released their quarterly earnings on Aug 13, 2026:
- Revenue of $20.85M misses estimates by $0, with -9.47% YoY decline.
- EPS of -0.11 exceeds estimates by 0.11, with 78.00% YoY growth.
ADC Therapeutics SA is scheduled to release its earnings on Nov 10, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2